AN2 Therapeutics, Inc.
ANTX
$1.15
$0.043.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.32% | -41.57% | 40.99% | 11.69% | 13.13% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.92% | 32.23% | 3.59% | -15.21% | 6.72% |
| Change in Net Operating Assets | -79.61% | -252.41% | 340.37% | 67.59% | 41.41% |
| Cash from Operations | 28.47% | -101.48% | 56.08% | 16.53% | 18.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.54% | 233.62% | -136.75% | 13.72% | -37.39% |
| Cash from Investing | -36.54% | 233.62% | -136.75% | 13.72% | -37.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -100.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -100.00% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.21% | 88.76% | -280.45% | 224.42% | -77.05% |